Chaoju Eye Care Holdings Ltd. (2219) AI Stock Analysis

• Market Cap: HK$1.90B
• Dividend Yield: 9.29%
• Average Volume (3M): 722.53K
• Price to Earnings (P/E): 10.0
• Beta (1Y): 0.79
• Revenue Growth: -3.19%
• EPS Growth: -20.30%
• Country: HK
• Employees: 2,608
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.18
• Shares Outstanding: 707,510,500
• 10 Day Avg. Volume: 521,468
• 30 Day Avg. Volume: 722,533
• PEG Ratio: -0.63
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 1.33
• P/FCF Ratio: 5.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: HK$3.00 ▲(10.70% Upside)

Chaoju Eye Care Holdings Ltd. has a solid financial foundation and attractive valuation, which are significant strengths. However, the technical analysis indicates bearish momentum, which is a concern. The absence of earnings call insights and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for services and effective market positioning, supporting long-term business expansion.

Cash Flow Management

Strong cash flow management enhances liquidity and provides financial flexibility for strategic investments and operational stability.

Balance Sheet Health

A low debt-to-equity ratio indicates financial stability and reduces risk, allowing for sustainable growth and resilience against economic fluctuations.

Negative Factors

Net Profit Margin Decline

A declining net profit margin may signal cost pressures or inefficiencies, potentially impacting profitability and requiring strategic cost management.

Decreased Return on Equity

A decrease in return on equity suggests reduced profitability relative to shareholder equity, which may affect investor confidence and capital efficiency.

Earnings Volatility

Significant earnings volatility can create uncertainty in financial performance, potentially affecting strategic planning and investor perception.

Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model

Company Description

Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyopia correction, and myopia control, as well as optical products and services. The company also provides basic ophthalmic services, including cataract, glaucoma, ocular fundus diseases, ocular muscle diseases, refraction errors, pediatric ophthalmology, ocular surface diseases, lacrimal diseases, orbital diseases, oculoplastic, and ocular trauma. As of December 31, 2021, it operated a network of 17 ophthalmic hospitals, 24 optical centers, and 2 clinics in Zhejiang, Jiangsu, Shanxi, and Hebei provinces, as well as in Inner Mongolia. The company was founded in 1988 and is headquartered in Beijing, China.

How the Company Makes Money

Chaoju Eye Care Holdings Ltd. generates revenue through multiple streams, primarily from the sale of its core products such as intraocular lenses and surgical instruments used in eye care procedures. The company benefits from a growing demand for ophthalmic surgeries due to an increasing prevalence of eye-related disorders among the aging population. Additionally, it engages in partnerships with hospitals and healthcare providers, enhancing its distribution network and access to a broader customer base. The company may also explore opportunities in research collaborations and government contracts, contributing to its overall earnings.

Chaoju Eye Care Holdings Ltd. Financial Statement Overview

Summary

Chaoju Eye Care Holdings Ltd. is in a solid financial position with consistent revenue growth, strong profitability margins, a healthy balance sheet, and robust cash flow management. The company maintains low leverage and a strong equity base, which provides financial stability and potential for future growth. While net profit margins decreased slightly, the company continues to generate strong cash flows, indicating sustainable operations.

Income Statement

Chaoju Eye Care Holdings Ltd. shows steady revenue growth, with a noticeable increase from 2019 to 2024. The gross profit margin has been consistent around 43-44%, indicating strong operational efficiency. However, the net profit margin saw a slight decline from 16.7% in 2023 to 13.9% in 2024, suggesting potential cost pressures or increased expenses. EBIT and EBITDA margins remain healthy, reflecting good earnings before interest, taxes, depreciation, and amortization.

Balance Sheet

The company's balance sheet is strong, with a low debt-to-equity ratio of 0.094 in 2024, indicating low leverage and financial stability. The return on equity is solid, although it decreased slightly from 9.7% in 2023 to 8.4% in 2024, reflecting reduced net income. The equity ratio remains robust at approximately 80%, showing a strong capital structure.

Cash Flow

Chaoju Eye Care demonstrates strong cash flow management, with operating cash flow consistently exceeding net income. The free cash flow grew significantly by 23.9% from 2023 to 2024, indicating improved cash generation capabilities. The free cash flow to net income ratio is high, suggesting efficient cash conversion and strong liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.37B	1.41B	1.37B	990.04M	997.79M	794.28M
Gross Profit	573.00M	611.30M	621.13M	434.70M	448.67M	349.48M
EBITDA	316.81M	335.37M	434.82M	267.87M	304.65M	225.18M
Net Income	172.27M	195.08M	228.91M	187.75M	161.75M	124.14M
Balance Sheet
Total Assets	3.00B	2.88B	2.92B	2.72B	2.51B	1.09B
Cash, Cash Equivalents and Short-Term Investments	1.47B	1.54B	1.55B	1.68B	1.78B	413.25M
Total Debt	253.76M	218.01M	200.80M	196.16M	178.65M	142.36M
Total Liabilities	638.53M	554.76M	544.38M	424.68M	378.11M	325.48M
Stockholders Equity	2.35B	2.32B	2.36B	2.27B	2.11B	737.25M
Cash Flow
Free Cash Flow	279.75M	354.36M	286.02M	148.29M	189.18M	196.16M
Operating Cash Flow	361.45M	354.36M	372.57M	273.41M	249.39M	248.75M
Investing Cash Flow	-315.07M	245.36M	-654.10M	-464.77M	-578.51M	-35.45M
Financing Cash Flow	-160.85M	-292.30M	-204.01M	-165.43M	1.19B	-39.61M

Chaoju Eye Care Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2219, the sentiment is Positive. The current price of 2.71 is above the 20-day moving average (MA) of 2.68, above the 50-day MA of 2.66, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.98 is Neutral, neither overbought nor oversold. The STOCH value of 54.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2219.

Chaoju Eye Care Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	71 Outperform	HK$568.47M	6.89	5.33%	9.14%	0.47%	50.46%
1846	69 Neutral	HK$895.36M	11.85	6.35%	1.99%	-1.61%	-27.39%
2219	68 Neutral	HK$1.90B	10.01	7.31%	9.29%	-3.19%	-20.30%
1526	66 Neutral	HK$1.37B	4.71	20.47%	4.37%	-3.56%	-17.45%
3886	52 Neutral	HK$1.63B	-11.32	-4.66%	0.49%	-0.55%	45.36%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3309	47 Neutral	HK$1.89B	-16.14	-6.41%	1.20%	2.05%	-285.88%

Chaoju Eye Care Holdings Ltd. Corporate Events

Chaoju Eye Care Wins Three-Year Waiver to Appoint Executive Director as Joint Company Secretary

Chaoju Eye Care Holdings has appointed executive director Zhang Guangdi as joint company secretary for a three-year term effective 7 January 2026, alongside existing joint company secretary Lo Wai Kin Kent. Zhang, who has extensive management experience within the group and a background in financial management and hospital operations, will combine this new governance role with his current responsibilities in the group’s investment and Hong Kong eye care businesses.

Because Zhang does not formally meet the Hong Kong Listing Rules’ professional qualification requirements for a company secretary, the Stock Exchange has granted Chaoju a three-year waiver from strict compliance with Rules 3.28 and 8.17, on the condition that Zhang is assisted by Lo and that the waiver can be revoked in the event of material Listing Rules breaches. The arrangement strengthens continuity in the company’s senior management and corporate governance structure while placing regulatory safeguards around compliance during the waiver period.

The most recent analyst rating on (HK:2219) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Chaoju Eye Care Holdings Ltd. stock, see the HK:2219 Stock Forecast page.

Chaoju Eye Care Revamps Company Secretary Roles and Seeks New Listing Rules Waiver

Chaoju Eye Care Holdings has announced a reshuffle of its corporate governance and compliance functions, with joint company secretary and authorised representative Mr. Cheng Ching Kit resigning from his roles, including as process agent, effective 1 January 2026. The company has appointed governance professional Mr. Lo Wai Kin Kent as company secretary, authorised representative and process agent from the same date, leveraging his more than 10 years’ experience in company secretarial and corporate governance work and his professional qualifications in Hong Kong, the UK and Australia. In tandem, joint company secretary Mr. Zhang Guangdi has also resigned because an existing waiver from Hong Kong Listing Rules 3.28 and 8.17 required him to be assisted by Mr. Cheng; Chaoju has applied to the Stock Exchange for a new waiver so that Mr. Zhang can be reappointed, and will make a further announcement once this is granted, underscoring the company’s focus on maintaining regulatory compliance amid changes in key governance personnel.

The most recent analyst rating on (HK:2219) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Chaoju Eye Care Holdings Ltd. stock, see the HK:2219 Stock Forecast page.

Chaoju Eye Care Announces HK$50 Million Share Repurchase Plan

Chaoju Eye Care Holdings Ltd. has announced its intention to conduct an on-market share repurchase of up to HK$50 million, demonstrating confidence in its business outlook and aiming to create value for its shareholders. This move, subject to market conditions and regulatory compliance, reflects the company’s strategic decision to utilize its financial resources effectively while maintaining a solid financial position.

The most recent analyst rating on (HK:2219) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Chaoju Eye Care Holdings Ltd. stock, see the HK:2219 Stock Forecast page.